XENEISOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XENEISOL (XENEISOL).
XENEISOL is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
| Metabolism | Primarily metabolized by hepatic cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4, to active metabolite NORXENEISOL. |
| Excretion | Primarily hepatic metabolism followed by renal excretion of metabolites: 70% renal, 20% biliary/fecal, 10% unchanged in urine. |
| Half-life | Terminal elimination half-life is 4.5 hours (range 3.5-6 hours) in adults; prolonged to 8-12 hours in hepatic impairment. |
| Protein binding | 92-96% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.2 L/kg (0.8-1.6 L/kg), indicating extensive extravascular distribution. |
| Bioavailability | Oral: 75% (first-pass metabolism reduces bioavailability); intravenous: 100%. |
| Onset of Action | Intravenous: 2-5 minutes; Oral: 30-60 minutes. |
| Duration of Action | Intravenous: 2-4 hours; Oral: 4-6 hours. Duration is dose-dependent and may be extended with repeated dosing. |
| Molecular Weight | 312.4 |
10 mg orally once daily, titrated to a maximum of 20 mg daily based on response and tolerability.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-59 mL/min: 5 mg orally once daily; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg orally once daily; Child-Pugh C: contraindicated. |
| Pediatric use | Safety and efficacy not established; use not recommended. |
| Geriatric use | Initial dose of 5 mg orally once daily due to increased sensitivity and renal impairment. |
| 1st trimester | Avoid in first trimester unless benefit outweighs risk; associated with increased risk of spontaneous abortion and congenital malformations based on animal studies and limited human data. |
| 2nd trimester | Use only if clearly needed; potential for fetal growth restriction and oligohydramnios with prolonged use. |
| 3rd trimester | Contraindicated in third trimester due to risk of premature ductus arteriosus closure and persistent pulmonary hypertension in the newborn. |
Clinical note
Comprehensive clinical and safety monograph for XENEISOL (XENEISOL).
| Placental transfer | Crosses the placenta; detected in fetal plasma with a cord-to-maternal ratio of approximately 0.5-0.8. |
| Breastfeeding | Excreted in human milk in low concentrations; use caution, especially with high maternal doses or prolonged exposure. Monitor infant for potential adverse effects such as gastrointestinal disturbances or renal impairment. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
History of hypersensitivity to XENEISOL or any of its excipientsThird trimester of pregnancyBreastfeeding in mothers with infants less than 1 month of age or with renal impairment
| Precautions | Serotonin syndrome with co-administration of other serotonergic drugs, Discontinuation syndrome upon abrupt cessation, Increased risk of bleeding with NSAIDs or anticoagulants, Hyponatremia in elderly or volume-depleted patients, Activation of mania/hypomania |
| Food/Dietary | Avoid grapefruit and grapefruit juice, as they inhibit CYP3A4 and increase XENEISOL exposure. Also avoid St. John's wort, which induces CYP3A4 and reduces efficacy. Limit alcohol as it may potentiate central nervous system depression. No other food restrictions noted. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations, particularly neural tube defects and cardiac anomalies, in animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Late third trimester: Potential neonatal complications including persistent pulmonary hypertension and renal impairment. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes. Serial fetal ultrasound for growth, amniotic fluid volume, and ductus arteriosus patency. Non-stress test or biophysical profile weekly after 28 weeks. Neonatal assessment for renal function and pulmonary hypertension at birth. |
| Fertility Effects | Reversible impairment of spermatogenesis in males; reduced ovarian reserve in females based on animal data. May delay time to conception. Contraceptive counseling recommended. |
| Clinical Pearls | XENEISOL is a CYP3A4 substrate; avoid coadministration with strong inhibitors or inducers. Monitor for QT prolongation, especially in patients with electrolyte imbalances or concurrent use of other QT-prolonging agents. Rapid infusion may cause hypotension; administer over at least 60 minutes. Dose adjustment required for creatinine clearance less than 30 mL/min. |
| Patient Advice | Take exactly as prescribed; do not change dose or stop without consulting your healthcare provider. · Avoid grapefruit and grapefruit juice while on this medication. · Report any signs of irregular heartbeat, fainting, or severe dizziness immediately. · Do not drive or operate heavy machinery until you know how XENEISOL affects you. · Stay hydrated but avoid excessive consumption of caffeine or alcohol. · Inform all healthcare providers that you are taking XENEISOL. |